Mitosis and apoptosis: How is the balance set?

Caroline H. Topham, Stephen S. Taylor

    Research output: Contribution to journalArticlepeer-review


    Anti-mitotic agents are used extensively during cancer chemotherapy. These agents target microtubules and thus block mitotic progression by activating the spindle assembly checkpoint. Following a prolonged mitotic arrest, cells either die in mitosis via apoptosis, or exit mitosis without dividing and survive, a process known as slippage. What dictates the balance between these two fates is unclear, but recent advances highlight the importance of the pro-survival Bcl2 family, with Mcl1 degradation emerging as a key determinant of mitotic cell fate. Here we review these advances, with a view towards identifying how the balance between apoptosis and slippage can be tipped in favour of death. This in turn may open up new opportunities to sensitize cancer cells to anti-mitotic agents. © 2013 Elsevier Ltd.
    Original languageEnglish
    Pages (from-to)780-785
    Number of pages5
    JournalCurrent opinion in cell biology
    Issue number6
    Publication statusPublished - Dec 2013


    Dive into the research topics of 'Mitosis and apoptosis: How is the balance set?'. Together they form a unique fingerprint.

    Cite this